Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002752 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002752: Completed Phase 1 study, sponsored by Duke University.
NCT00002752 is a Phase 1 study that has completed, run by Duke University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002752, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have primary or metastatic brain cancer.
Interventions
- RADIATION iodine I 131 monoclonal antibody 81C6
Trial Details
| Field | Value |
|---|---|
| Start Date | 1993-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
What the finished NCT00002752 record still lists
NCT00002752 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which iodine I 131 monoclonal antibody 81C6 is the first listed.
NCT00002752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002752 about?
NCT00002752 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have primary ...
What is the current status of trial NCT00002752?
This trial is currently completed. It is a Phase 1 study. The study started on 1993-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00002752?
The interventions under investigation include: iodine I 131 monoclonal antibody 81C6 (RADIATION).
Who is sponsoring clinical trial NCT00002752?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia